Literature DB >> 12063828

Early detection of pancreatic carcinoma.

Christophe Rosty1, Michael Goggins.   

Abstract

The poor prognosis and late presentation of pancreatic cancer patients emphasize the importance of an effective early detection strategy for patients at risk of developing pancreatic cancer. In current practice, the use of CA 19-9 levels and imaging techniques is not optimal for detecting small pancreatic lesions. It is hoped that the understanding of genetic alterations in combination with the development of high-throughput sensitive techniques will lead to the rapid discovery of a panel of biomarkers that will save lives by enabling aggressive therapy at the time when tumors are curable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063828     DOI: 10.1016/s0889-8588(01)00007-7

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  44 in total

Review 1.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

2.  New tumor-associated antigen SC6 in pancreatic cancer.

Authors:  Min-Pei Liu; Xiao-Zhong Guo; Jian-Hua Xu; Di Wang; Hong-Yu Li; Zhong-Min Cui; Jia-Jun Zhao; Li-Nan Ren
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins.

Authors:  Rui Tian; Li-Ming Wei; Ren-Yi Qin; Yan Li; Zhi-Yong Du; Wei Xia; Cheng-Jian Shi; Hong Jin
Journal:  Dig Dis Sci       Date:  2007-05-11       Impact factor: 3.199

Review 4.  Molecular markers of pancreatic cancer: development and clinical relevance.

Authors:  Lucia C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

5.  The identification of auto-antibodies in pancreatic cancer patient sera using a naturally fractionated Panc-1 cell line.

Authors:  Chen Li; Hye-Yeung Kim; Huy Vuong; Tasneem Patwa; Manoj Pal; Randall E Brand; Diane M Simeone; David M Lubman
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 6.  Target discovery and validation in pancreatic cancer.

Authors:  Robert M Beaty; Mads Gronborg; Jonathan R Pollack; Anirban Maitra
Journal:  Methods Mol Biol       Date:  2007

Review 7.  Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.

Authors:  Si-Biao Su; Shan-Yu Qin; Wen Chen; Wei Luo; Hai-Xing Jiang
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

8.  Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China.

Authors:  Yong Chen; JiHui Hao; WeiDong Ma; Yong Tang; ChunTao Gao; XiShan Hao
Journal:  J Gastrointest Surg       Date:  2011-04-12       Impact factor: 3.452

9.  Mitochondrial DNA mutations in pancreatic cancer.

Authors:  Keyanoosh Kassauei; Nils Habbe; Michael E Mullendore; Collins A Karikari; Anirban Maitra; Georg Feldmann
Journal:  Int J Gastrointest Cancer       Date:  2006

10.  Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.

Authors:  Reiko Takayama; Hidewaki Nakagawa; Akira Sawaki; Nobumasa Mizuno; Hiroki Kawai; Masahiro Tajika; Yasushi Yatabe; Keitaro Matsuo; Rie Uehara; Ken-ichiro Ono; Yusuke Nakamura; Kenji Yamao
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.